General

Guideline Title


Bibliographic Source(s)


Guideline Status

This is the current release of the guideline.


Recommendations

Major Recommendations

The grades of recommendation (1A, 1B, 1C, 2A, 2B, 2C) and the approach to rating the quality of evidence are defined at the end of the "Major Recommendations" field.

Maternal Complications of Antithrombotic Therapy Use during Pregnancy

Low-Molecular-Weight Heparin (LMWH) Therapy

For pregnant patients, the expert panel recommends LMWH for the prevention and treatment of venous thromboembolism (VTE), instead of unfractionated heparin (UFH) (Grade 1B).

Fetal Complications of Antithrombotic Therapy during Pregnant Women

For women receiving anticoagulation for the treatment of VTE who become pregnant, the expert panel recommends LMWH over vitamin K antagonists (VKA) during the first trimester (Grade 1A), in the second and third trimesters (Grade 1B), and during late pregnancy when delivery is imminent (Grade 1A).

For women requiring long-term VKAs who are attempting pregnancy and are candidates for LMWH substitution, the expert panel suggests performing frequent pregnancy tests and substituting LMWH for VKAs when pregnancy is achieved rather than switching to LMWH while
attempts pregnancy (Grade 2C).

Remarks: Women who place little value on avoiding the risks, inconvenience, and costs of LMWH therapy of uncertain duration while awaiting pregnancy and a high value on minimizing the risks of early miscarriage associated with VKA therapy are likely to choose LMWH while attempting pregnancy.

For pregnant women, the expert panel suggests limiting the use of fondaparinux and parenteral direct thrombin inhibitors to those with severe allergic reactions to heparin (e.g., heparin-induced thrombocytopenia [HIT]) who cannot receive danaparoid (Grade 2C).

For pregnant women, the expert panel recommends avoiding the use of oral direct thrombin (e.g., dabigatran) and anti-Xa (e.g., rivaroxaban, apixaban) inhibitors (Grade 1C).

Use of Anticoagulants in Breast-Feeding Women

For lactating women using warfarin, acenocoumarol, or UFH who wish to breast-feed, the expert panel recommends continuing the use of warfarin, acenocoumarol, or UFH (Grade 1A).

For lactating women using LMWH, danaparoid, or r-hirudin who wish to breast-feed, the expert panel recommends continuing the use of LMWH, danaparoid, or r-hirudin (Grade 1B).

For breast-feeding women, the expert panel suggests alternative anticoagulants rather than fondaparinux (Grade 2C).

For breast-feeding women, the expert panel recommends alternative anticoagulants rather than oral direct thrombin (e.g., dabigatran) and factor Xa inhibitors (e.g., rivaroxaban, apixaban) (Grade 1C).

Use of Anticoagulants in Breast-Feeding Women

For lactating women using low-dose aspirin for vascular indications who wish to breast-feed, the expert panel suggests continuing this medication (Grade 2C).

VTE in Patients Using Assisted Reproductive Technology

Prevention of VTE in Patients Undergoing Assisted Reproductive Technology

For women undergoing assisted reproduction, the expert panel recommends against the use of routine thrombosis prophylaxis (Grade 1B).

For women undergoing assisted reproduction who develop severe ovarian hyperstimulation syndrome, the expert panel suggests thrombosis prophylaxis (prophylactic LMWH) for 3 months postresolution of clinical ovarian hyperstimulation syndrome rather than no prophylaxis (Grade 2C).

Remarks: Women who are averse to taking medication for very small benefit and those who consider self-injecting a considerable burden will be disinclined to use LMWH for extended thrombosis prophylaxis. Given that the absolute benefit decreases as time from the hyperstimulation event increases, such women will be very disinclined to continue prophylaxis throughout the entire resultant pregnancy.

VTE Following Cesarean Section

Thromboprophylaxis Following Caesarean Section

For women undergoing cesarean section without additional thrombosis risk factors, the expert panel recommends against the use of thrombosis prophylaxis other than early mobilization (Grade 1B).

For women at increased risk of VTE after cesarean section because of the presence of one major or at least two minor risk factors (see Table 3 in the original guideline document, "Risk Factors for VTE Resulting in a Baseline Risk of Postpartum VTE of >3%"), the expert panel suggests pharmacologic thromboprophylaxis (prophylactic LMWH) or mechanical prophylaxis (elastic stockings or intermittent pneumatic compression) in those with contraindications to anticoagulants while in hospital following delivery rather than no prophylaxis (Grade 2B).

Remarks: The reduced bleeding risk with mechanical prophylaxis should be weighed against the inconvenience of elastic stockings and intermittent pneumatic compression.

For women undergoing cesarean section who are considered to be at very high risk for VTE and who have multiple additional risk factors for thromboembolism that persist in the puerperium, the expert panel suggests that prophylactic LMWH be combined with elastic stockings and/or intermittent pneumatic compression over LMWH alone (Grade 2C).

For selected high-risk patients in whom significant risk factors persist following delivery, the expert panel suggests extended prophylaxis (up to 6
weeks after delivery) following discharge from the hospital (Grade 2C).

**Treatment of Proven Acute VTE during Pregnancy**

**For pregnant women with acute VTE, the expert panel recommends therapy with adjusted-dose subcutaneous (SC) LMWH over adjusted-dose UFH (Grade 1B).**

**For pregnant women with acute VTE, the expert panel recommends LMWH over VKA treatment antenatally (Grade 1A).**

**For pregnant women with acute VTE, the expert panel suggests that anticoagulants should be continued for at least 6 weeks postpartum (for a minimum total duration of therapy of 3 months) in comparison with shorter durations of treatment (Grade 2C).**

**For pregnant women receiving adjusted-dose LMWH therapy and where delivery is planned, the expert panel recommends discontinuation of LMWH at least 24 h prior to induction of labor or cesarean section (or expected time of neuraxial anesthesia) rather than continuing LMWH up until the time of delivery (Grade 1B).**

**Prevention of VTE in Pregnant Women with Prior Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)**

**Prevention of Recurrent VTE in Pregnant Women**

For all pregnant women with prior VTE, the expert panel suggests postpartum prophylaxis for 6 weeks with prophylactic- or intermediate-dose LMWH or VKAs targeted at INR 2.0 to 3.0 rather than no prophylaxis (Grade 2B).

**For pregnant women at low risk of recurrent VTE (single episode of VTE associated with a transient risk factor not related to pregnancy or use of estrogen), the expert panel suggests clinical vigilance antepartum rather than antepartum prophylaxis (Grade 2C).**

**For pregnant women at moderate to high risk of recurrent VTE (single unprovoked VTE, pregnancy- or estrogen-related VTE, or multiple prior unprovoked VTE not receiving long-term anticoagulation), the expert panel suggests antepartum prophylaxis with prophylactic- or intermediate-dose LMWH rather than clinical vigilance or routine care (Grade 2C).**

**For pregnant women receiving long-term VKAs, the expert panel suggests adjusted-dose LMWH or 75% of a therapeutic dose of LMWH throughout pregnancy followed by resumption of long-term anticoagulants postpartum, rather than prophylactic-dose LMWH (Grade 2C).**

**Prevention of VTE in Pregnant Women with Thrombophilia and No Prior VTE**

**Prevention of Pregnancy-Related VTE in Women with Thrombophilia**

For pregnant women with no prior history of VTE who are known to be homozygous for factor V Leiden or the prothrombin 20210A mutation and have a positive family history for VTE, the expert panel suggests antepartum prophylaxis with prophylactic- or intermediate-dose LMWH and postpartum prophylaxis for 6 weeks with prophylactic- or intermediate-dose LMWH or VKAs targeted at INR 2.0 to 3.0 rather than no prophylaxis (Grade 2B).

**For pregnant women with all other thrombophilias and no prior VTE who have a positive family history for VTE, the expert panel suggests antepartum clinical vigilance and postpartum prophylaxis with prophylactic- or intermediate-dose LMWH or, in women who are not protein C or S deficient, VKAs targeted at INR 2.0 to 3.0 rather than routine care (Grade 2C).**

**For pregnant women with no prior history of VTE who are known to be homozygous for factor V Leiden or the prothrombin 20210A mutation and who do not have a positive family history for VTE, the expert panel suggests antepartum clinical vigilance and postpartum prophylaxis for 6 weeks with prophylactic- or intermediate-dose LMWH or VKAs targeted at INR 2.0 to 3.0 rather than routine care (Grade 2B).**

**For pregnant women with all other thrombophilias and no prior VTE who do not have a positive family history for VTE, the expert panel suggests antepartum and postpartum clinical vigilance rather than pharmacologic prophylaxis (Grade 2C).**

**Thrombophilia and Pregnancy Complications**

**Prevention of Pregnancy Complications in Women with Thrombophilia**

For women with recurrent early pregnancy loss (three or more miscarriages before 10 weeks of gestation), the expert panel recommends screening for antiphospholipid antibodies (APLAs) (Grade 1B).
For women with a history of pregnancy complications, the expert panel suggests not to screen for inherited thrombophilia (Grade 2C).

For women who fulfill the laboratory criteria for APLA syndrome and meet the clinical APLA criteria based on a history of three or more pregnancy losses, the expert panel recommends antepartum administration of prophylactic- or intermediate-dose UFH or prophylactic LMWH combined with low-dose aspirin, 75 to 100 mg/day, over no treatment (Grade 1B).

For women with inherited thrombophilia and a history of pregnancy complications, the expert panel suggests not to use antithrombotic prophylaxis (Grade 2C).

Management of Women with a History of Preeclampsia or Recurrent Fetal Loss and No Thrombophilia

Prevention of Recurrent Preeclampsia in Women with No Thrombophilia

For women considered at risk for preeclampsia, the expert panel recommends low-dose aspirin throughout pregnancy, starting from the second trimester, over no treatment (Grade 1B).

Women without Known Thrombophilia and at Least Two Prior Pregnancy Losses

For women with two or more miscarriages but without APLA or thrombophilia, the expert panel recommends against antithrombotic prophylaxis (Grade 1B).

Maternal and Fetal Risks Related to Anticoagulation During Pregnancy for Mechanical Prosthetic Valves

For pregnant women with mechanical heart valves, the expert panel recommends one of the following anticoagulant regimens in preference to no anticoagulation (all Grade 1A):

a. Adjusted-dose twice a day (bid) LMWH throughout pregnancy. The expert panel suggests that doses be adjusted to achieve the manufacturer's peak anti-Xa LMWH 4 h post subcutaneous injection or

b. Adjusted-dose UFH throughout pregnancy administered subcutaneously every 12 h in doses adjusted to keep the mid-interval activated partial thromboplastin time (aPTT) at least twice control or attain an anti-Xa heparin level of 0.35 to 0.70 units/mL or

c. UFH or LMWH (as above) until the 13th week, with substitution by VKAs until close to delivery when UFH or LMWH is resumed.

Remarks: For pregnant women with mechanical heart valves, the decision regarding the choice of anticoagulant regimen is so value and preference dependent (risk of thrombosis vs risk of fetal abnormalities) that the expert panel considers the decision to be completely individualized. Women of childbearing age and pregnant women with mechanical valves, should be counseled about potential maternal and fetal risks associated with various anticoagulant regimens, including continuation of VKAs with substitution by LMWH or UFH close to term, substitution of VKAs by LMWH or UFH until the 13th week and then close to term, and use of LMWH or UFH throughout pregnancy. Usual long-term anticoagulants should be resumed postpartum when adequate hemostasis is assured.

In women judged to be at very high risk of thromboembolism in whom concerns exist about the efficacy and safety of UFH or LMWH as dosed above (e.g., older generation prosthesis in the mitral position or history of thromboembolism), the expert panel suggests VKAs throughout pregnancy with replacement by UFH or LMWH (as above) close to delivery rather than one of the regimens above (Grade 2C).

Remarks: The recommendation for women at very high risk of thromboembolism places a higher value on avoiding maternal complications (e.g., catastrophic valve thrombosis) than on avoiding fetal complications. Women who place a higher risk on avoiding fetal risk will choose LMWH or UFH over vitamin K antagonists.

For pregnant women with prosthetic valves at high risk of thromboembolism, the expert panel suggests the addition of low-dose aspirin, 75 to 100 mg/day (Grade 2C).

Definitions:

Grading of Recommendations Assessment, Development and Evaluation (GRADE) Approach to Rating Quality of Evidence

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Quality of Evidence</th>
<th>Lower if</th>
<th>Higher if</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomized Trial →</td>
<td>High</td>
<td>Risk of bias</td>
<td>Large effect</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-1 Serious</td>
<td>+1 Large</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-2 Very serious</td>
<td>+2 Very large</td>
</tr>
<tr>
<td>Moderate</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Strength of the Recommendations Grading System

<table>
<thead>
<tr>
<th>Grade of Recommendation*</th>
<th>Benefit vs. Risk and Burdens</th>
<th>Methodologic Quality of Supporting Evidence</th>
<th>Implications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong recommendation, high-quality evidence, Grade 1A</td>
<td>Benefits clearly outweigh risk and burdens or vice versa</td>
<td>Consistent evidence from randomized controlled trials (RCTs) without important limitations or exceptionally strong evidence from observational studies</td>
<td>Recommendation can apply to most patients in most circumstances. Further research is very unlikely to change confidence in the estimate of effect</td>
</tr>
<tr>
<td>Strong recommendation, moderate-quality evidence, Grade 1B</td>
<td>Benefits clearly outweigh risk and burdens or vice versa</td>
<td>Evidence from RCTs with important limitations (inconsistent results, methodologic flaws, indirect or imprecise), or very strong evidence from observational studies</td>
<td>Recommendation can apply to most patients in most circumstances. Higher quality research may well have an important impact on confidence in the estimate of effect and may change the estimate</td>
</tr>
<tr>
<td>Strong recommendation, low- or very-low-quality evidence, Grade 1C</td>
<td>Benefits clearly outweigh risk and burdens or vice versa</td>
<td>Evidence for at least one critical outcome from observational studies, case series, or from RCTs with serious flaws or indirect evidence</td>
<td>Recommendation can apply to most patients in many circumstances. Higher-quality research is likely to have an important impact on confidence in the estimate of effect and may well change the estimate</td>
</tr>
<tr>
<td>Weak recommendation, high-quality evidence, Grade 2A</td>
<td>Benefits closely balanced with risks and burden</td>
<td>Consistent evidence from RCTs without important limitations or exceptionally strong evidence from observational studies</td>
<td>The best action may differ depending on circumstances or patient or society values. Further research is very unlikely to change confidence in the estimate of effect</td>
</tr>
<tr>
<td>Weak recommendation, moderate-quality evidence, Grade 2B</td>
<td>Benefits closely balanced with risks and burden</td>
<td>Evidence from RCTs with important limitations (inconsistent results, methodologic flaws, indirect or imprecise) or very strong evidence from observational studies</td>
<td>Best action may differ depending on circumstances or patient or society values. Higher-quality research may well have an important impact on confidence in the estimate of effect and may change the estimate</td>
</tr>
<tr>
<td>Weak recommendation, low- or very-low-quality evidence, Grade 2C</td>
<td>Uncertainty in the estimates of benefits, risks, and burden; benefits, risk, and burden may be closely balanced</td>
<td>Evidence for at least one critical outcome from observational studies, case series, or RCTs, with serious flaws or indirect evidence</td>
<td>Other alternatives may be equally reasonable. Higher-quality research is likely to have an important impact on confidence in the estimate of effect and may well change the estimate</td>
</tr>
</tbody>
</table>

*The guideline developers use the wording recommend for strong (Grade 1) recommendations and suggest for weak (Grade 2) recommendations.*

### Clinical Algorithm(s)

None provided
Scope

Disease/Condition(s)
- Venous thromboembolism (VTE) during pregnancy or following caesarean section
- Pregnancy-related VTE in hereditary thrombophilia
- Pregnancy complications in hereditary thrombophilia
- Recurrent preeclampsia or recurrent pregnancy loss
- Thromboembolism related to mechanical heart values during pregnancy
- Any disease or condition requiring antithrombotic therapy during pregnancy or lactation

Guideline Category
Management
Prevention
Treatment

Clinical Specialty
Cardiology
Critical Care
Emergency Medicine
Family Practice
Hematology
Internal Medicine
Obstetrics and Gynecology
Pediatrics
Pulmonary Medicine

Intended Users
Advanced Practice Nurses
Health Care Providers
Nurses
Pharmacists
Physician Assistants
Physicians

Guideline Objective(s)
- To update evidence-based recommendations for the use of anticoagulant therapy for the management of thromboembolic conditions
To offer guidance for many common anticoagulation-related management problems
To optimize patient-important health outcomes and the processes of care for patients who have experienced or are at risk for thrombotic events
To provide evidence-based guidelines the management of venous thromboembolism and thrombophilia as well as the use of antithrombotic agents during pregnancy

Target Population
- Pregnant and lactating women who require antithrombotic therapy for venous thromboembolism prevention or treatment
- Pregnant women with thrombophilia

Interventions and Practices Considered
1. Antithrombotic therapies before or during pregnancy and while breastfeeding
   - Unfractionated heparin (UFH)
   - Low-molecular-weight heparin (LMWH)
   - Vitamin K antagonists
   - Aspirin
   - Graduated compression stockings
   - Intermittent pneumatic compression
   - Antepartum and postpartum duration of therapy
   - Discontinuation of therapy prior to induction of labor
   - Monitoring (activated partial thromboplastin time [APTT], anti-Xa LMWH or UFH levels)
   - Vigilance with no prophylactic therapy
2. Screening for antiphospholipid antibodies (APLAs) (in women with recurrent early pregnancy loss or unexplained late pregnancy loss, severe or recurrent preeclampsia or intrauterine growth restriction [IUGR])

Major Outcomes Considered
- Fetal outcomes (pregnancy loss, congenital malformations)
- Maternal mortality (mortality, venous thromboembolism [VTE] and pulmonary embolism [PE], major maternal hemorrhage)
- Burden of treatment

Methodology

Methods Used to Collect/Select the Evidence
Hand-searches of Published Literature (Primary Sources)
Hand-searches of Published Literature (Secondary Sources)
Searches of Electronic Databases

Description of Methods Used to Collect/Select the Evidence
Defining the Clinical Questions—Population, Intervention, Comparator, and Outcome
The thrombosis expert on the Executive Committee along with the deputy editors took primary responsibility for defining the scope of the clinical questions that each article would address. For each question, the topic editor and deputy editor defined the relevant population, alternative management strategies (intervention and comparator), and the outcomes (i.e., population, intervention, comparator, and outcome [PICO] format). Each clinical question provided the framework for formulating study inclusion and exclusion criteria and guided the search for relevant evidence.
Identifying the Evidence

To identify the relevant evidence, a team of methodologists and medical librarians at the Oregon Health & Science University Evidence-based Practice Center conducted literature searches of Medline, the Cochrane Library, and the Database of Abstracts of Reviews of Effects. For each article, the team conducted a search for systematic reviews and another for original studies encompassing the main populations and interventions for that article. These searches included studies indexed from week 1, January 2005, forward because Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th Edition (AT8) searches were carried out up to that date (search strategies are available on request). Many articles supplemented these searches with more-focused searches addressing specific clinical questions. When clinical questions had not been covered in AT8, searches commenced at a date relevant to each intervention.

Titles and abstracts retrieved from bibliographic database searches generally were screened in duplicate, and full-text articles were retrieved for further review. Consensus on whether individual studies fulfilled inclusion criteria was achieved for each study between two reviewers. If consensus could not be achieved, the topic editor and other topic panelists were brought into the discussion. Deputy editors reviewed lists of included studies from the database searches in order to identify any potentially missed studies. Additional studies identified were then retrieved for further evaluation.

Topic panels also searched the same bibliographic databases for systematic reviews addressing each PICO question. The quality of reviews was assessed using principles embodied in prior instruments addressing methodologic quality of systematic reviews, and wherever possible, current high-quality systematic reviews were used as the source of summary estimates. Reviews were also used to identify additional studies to complement the database searches.

Number of Source Documents

Not stated

Methods Used to Assess the Quality and Strength of the Evidence

Weighting According to a Rating Scheme (Scheme Given)

Rating Scheme for the Strength of the Evidence

Grading of Recommendations Assessment, Development and Evaluation (GRADE) Approach to Rating Quality of Evidence

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Quality of Evidence</th>
<th>Lower if</th>
<th>Higher if</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomized Trial</td>
<td>High</td>
<td>Risk of bias</td>
<td>Large effect</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-1 Serious</td>
<td>+1 Large</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-2 Very serious</td>
<td>+2 Very large</td>
</tr>
<tr>
<td></td>
<td>Moderate</td>
<td>Inconsistency</td>
<td>Dose response</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-1 Serious</td>
<td>+1 Evidence of a gradient</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-2 Very serious</td>
<td></td>
</tr>
<tr>
<td>Observational Study</td>
<td>Low</td>
<td>Indirectness</td>
<td>All plausible confounding</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-1 Serious</td>
<td>+1 Would produce a demonstrated effect or</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-2 Very serious</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Very Low</td>
<td>Imprecision</td>
<td>+1 Would suggest a spurious effect when</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-1 Serious</td>
<td>result show no effect</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-2 Very serious</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Imprecision</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>-1 Serious</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>-2 Very serious</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Publication bias</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>-1 Likely</td>
<td></td>
</tr>
</tbody>
</table>
Methods Used to Analyze the Evidence

Review of Published Meta-Analyses

Systematic Review with Evidence Tables

Description of the Methods Used to Analyze the Evidence

General Methods

Assessing Studies and Summarizing Evidence

Evaluating Risk of Bias in Individual Studies

The expert panel developed and applied uniform criteria for evaluating the risk of bias associated with individual randomized controlled trials (RCTs) based on the criteria recommended by the Cochrane Collaboration (Table 1 in the methodology companion [see the "Availability of Companion Documents" field]). Although all authors assessed risk of bias for individual studies, because of resource limitations, the panel summarized the results of the risk of bias for only a minority of the recommendations. Readers can find these assessments in the online data supplements. For most recommendations for which such tables were not developed, Evidence Profiles that typically provide information on the risk of bias in footnotes were developed.

The panel also developed specific criteria for assessing the risk of bias of observational studies (cohort studies with concurrent controls, cohort studies with historical controls, case-control studies, or case series). Again, these were based on the evidence-based domains recommended by the Cochrane Collaboration for observational studies.

Studies without internal comparisons were termed "cohort studies without internal controls" if they met the following criteria:

1. A protocol existed before the date of commencement of data collection.
2. A definition of inclusion and exclusion criteria was available.
3. The study reported the number of excluded patients.
4. The study conducted a standardized follow-up, including description of all of the following: schedule of follow-up, investigation of suspected outcomes, and criteria used to define outcomes.
5. The study reported all losses to follow-up.

The panel labeled studies that did not meet these criteria as "case series." No distinction was made between prospective and retrospective studies because although prospective studies may on average be of higher quality, individual prospective studies may have a significant risk of bias and specific retrospective studies may not. For questions related to risk assessment, the panel evaluated the risk of bias of individual studies using the following criteria: valid outcome assessment, including blinding when appropriate; adjustment for between-group differences; and minimal loss to follow-up.

Evaluating Quality of Bodies of Evidence

The expert panel assessed evidence across studies on an outcome-by-outcome basis using criteria suggested by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group. The expert panel defined quality of evidence as their confidence in the estimate of the effect to support a recommendation. RCTs start as high-quality evidence and observational studies as low-quality evidence. Additional factors that affect this rating of quality include the risk of bias; precision, consistency, and directness of results; likelihood of publication bias; and presence of very large effects. The American College of Chest Physicians (ACCP) adaptation of the GRADE system differs only in that the quality of a body of evidence can be high (A), moderate (B), or low (C); GRADE also provides a category for very-low-quality evidence. See the "Rating Scheme for the Strength of the Evidence" field.

Often, the panel found that the quality of the evidence differed across outcomes. For example, in assessing the quality of evidence for thienopyridines vs warfarin in patients undergoing percutaneous coronary interventions, the panel determined the evidence to be of moderate quality for mortality, nonfatal myocardial infarction, and revascularization but of low quality for major bleeding.

The panel then made a rating of the quality of the entire body of evidence bearing on the effect of alternative management strategies for each clinical
question. In other words, the panel assessed the quality across outcomes, including both benefits and harms. Quality for each recommendation was the lowest quality rating of the outcomes judged as critical (as opposed to important, but not critical).

Most patient-important outcomes in this guideline are binary or yes-no outcomes (death, stroke, venous thromboembolism [VTE], myocardial infarction, bleeding). In general, relative effects are similar across subgroups of patients, including those with varying baseline risk. The evidence summaries (Evidence Profiles and Summary of Findings tables), therefore, include a presentation of relative effects (where possible as relative risks because they are easier to understand than odds ratios [ORs]) of intervention vs control management strategies.

Trading off desirable and undesirable consequences (e.g., thrombosis vs bleeding) requires, however, estimates of absolute effect. For example, in patients with atrial fibrillation, warfarin results in a 66% relative risk reduction in nonfatal stroke. This comes at a cost of inconvenience, lifestyle restrictions, and risk of bleeding. For patients with a CHADS (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke) score of ≥3, the 66% relative risk reduction translates into an absolute reduction of 6.3% (63 in 1,000) per year. Virtually all patients will consider this worthwhile. On the other hand, for patients with a CHADS score of 0, the 66% reduction translates into an absolute risk reduction of only 0.5% (5 in 1,000) per year. Many patients may consider this reduction not worth the undesirable consequences of warfarin use.

The panel calculated absolute effects by applying relative risks to estimates of control group risk. For instance, if control group risk of thrombosis is 4% and relative risk with an intervention is 50%, then the absolute difference between intervention and control is 4% of 50% or 2%, and the number needed to treat to prevent an episode of thrombosis is 100/2 or 50. In many cases, the Summary of Findings tables present effects as events prevented (or caused) per 1,000 patients. In this hypothetical example, the effect would be 20 events per 1,000 patients.

Whenever valid prognostic data were available from observational studies, they were used to estimate control group risks. When credible results from observational and prognostic studies were not available, risk estimates from control groups of RCTs were used.

**Considering Subgroup-Specific Relative and Absolute Effects**

Whenever the expert panel identified credible evidence that the relative effects vary across distinguishable subgroups of patients (i.e., interaction between the intervention and a patient characteristic), the respective relative effects were considered separately. The panel then calculated the associated absolute effects.

Even when the relative effect is the same, the absolute magnitude of treatment effects may differ in patients with varying levels of risk. For instance, although the relative risk reduction of warfarin vs aspirin in stroke prevention for patients with atrial fibrillation is likely close to 50% across risk groups, this translates into an absolute risk reduction of <1% per year in the lowest-risk groups and ~5% per year in the highest-risk groups.

The expert panel included control group risks and absolute-effect estimates for different groups in the summaries of effect when (and only when) two conditions were present. First, they required validated prognostic models or, at the very least, credible strategies for clinicians to easily identify higher- and lower-risk patients. Second, the panel identified varying risk groups only when recommendations differed in strength or direction between groups. Both conditions were met, for instance, in the atrial fibrillation recommendations in which strong recommendations in favor of anticoagulation were restricted to the higher-risk patients.

**Conducting Meta-analyses**

When pooled estimates of effects were not available from existing high-quality systematic reviews, the panel performed meta-analyses if the data were sufficiently homogeneous. When pooling two studies, they used a fixed-effects model. When three or more studies were available for generating a pooled estimate, they used a random-effects model as the primary analysis and a fixed-effects model as a secondary analysis. If there were discrepancies between the two, the panel considered the following reasons: If there was substantial heterogeneity leading to wider confidence intervals (CIs) with the random-effects model, the panel considered that model more trustworthy, and if the discrepancy was due to a single large dominant study with a result substantially different from smaller studies, they considered the fixed-effects model more trustworthy. The panel also assessed statistical heterogeneity using both a \( \chi^2 \) test and \( I^2 \) as well as assessed possible explanations of heterogeneity considering a priori-generated hypotheses.

**Summary Tables**

When resources permitted, the expert panel used a standardized approach for summarizing the evidence and methodology of individual studies. These summaries appear in the online data supplements. Wherever possible, the expert panel reported nonfatal events (e.g., nonfatal stroke) so that there is no overlap with the number of fatal events reported.

For a large number of recommendations, the expert panel summarized the quality of the body of evidence (see the "Rating Scheme for the Strength of the Evidence" field) and estimates of relative and absolute effect of alternative management strategies using the methods of the GRADE Working Group. Evidence Profiles summarize the quality of the body of evidence and when evidence comes from randomized trials, generally include a
presentation of reviewer assessment of risk of bias, precision, consistency, directness, and publication bias associated with each outcome. As specified in GRADE methodology, the overall quality of evidence represents the lowest quality of any critical outcome.

Evidence Profiles can be found in the online data supplement. The format for these tables was determined through a formal survey of panelists that evaluated the panelists' preferences for alternative presentations and the impact of these presentations on their understanding of the evidence. The text in the printed version of Antithrombotic Therapy and Prevention of Thrombosis, 9th ed (AT9) recommendations includes more succinct Summary of Findings tables, which include the overall quality assessment as well as the relative and absolute effect sizes for each outcome. Use of an associated computer program facilitated the production of the Evidence Profiles and Summary of Findings tables which are listed in the original guideline document.

Specific Methods for This Guideline

There is a paucity of high-quality studies addressing risk factors for the outcomes discussed in this article as well as for the risks and benefits of antithrombotic therapy during pregnancy. Most recommendations, therefore, are based on low- to moderate-quality evidence and mirror the panel's limited confidence in relative effect estimates from studies of antithrombotic treatment during pregnancy. To obtain baseline risk estimates for pregnancy complications, the panel summarizes available observational studies of pregnant women, including case reports and case series of pregnant women in the absence of studies with a cohort design. They then apply the baseline risk estimates to the relative risk estimates to establish anticipated absolute benefits and harms of intervention. In the absence of direct evidence from randomized trials of reasonable quality, indirect evidence from randomized trials in nonpregnant patients is considered applicable to the present patient population (e.g., the panel extrapolates the effect of thromboprophylaxis with low molecular weight heparin on the incidence of venous thromboembolism in patients undergoing general surgery to women undergoing cesarean section).

Refer to the original guideline for a discussion of the implications of women's preferences and values during pregnancy.

Methods Used to Formulate the Recommendations

Expert Consensus (Consensus Development Conference)

Description of Methods Used to Formulate the Recommendations

Composition and Selection of Topic Panel Members

The American College of Chest Physicians (ACCP) Antithrombotic Therapy and Prevention of Thrombosis, 9th ed (AT9) Executive Committee selected panel members for each article. A topic editor and a deputy editor led each of the AT9 panels issuing recommendations. The topic editor was the person primarily responsible for each article and was required to be a methodologist without serious financial or intellectual conflict of interest for any of the article's recommendations. In all but one case, the topic editor also was a clinician. The Executive Committee chose these individuals on the basis of their previous experience with guideline development and, in particular, their familiarity with methods developed by the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) Working Group. These topic editors and all panel members were approved by the ACCP Health and Science Policy (HSP) Committee after review of their conflict of interest disclosures.

Criteria for selection of the remainder of the panel members, including the deputy editor-thrombosis expert, were an established record in the relevant clinical or research area, international and gender representation, and an absence of financial conflicts of interest that were judged unacceptable. Some of the panelists had prior experience on ACCP guidelines in this area and represented the thrombosis community, but there was substantial turnover from the previous edition. After an international request for applications broadcast through multiple medical societies, the Executive Committee nominated individual topic editors and deputy editors and collaborated with them to identify and nominate other topic panel members.

The ACCP HSP Committee reviewed all nominees and approved all panel members after review of their curricula vitae and conflict of interest disclosures. Of 150 nominees, 137 were approved, 18 were approved with management of conflicts of interest (i.e., regular disclosures and review of ongoing conflicts as the process progressed), and 13 were disapproved as a result of the magnitude of financial conflicts of interest. Articles associated with recommendations included from seven to 14 panel members. Patients or representatives of specific stakeholder groups were not included on topic panels.

Each topic panel also included a frontline physician working in the relevant area who was neither an expert in thrombosis nor a methodologist or clinical investigator. These individuals were chosen in consultation with the topic editors and the ACCP HSP Committee. These clinicians were charged with the following (1) proposing important real-world clinical questions on the prevention, diagnosis, and treatment of thrombosis that
were not addressed in Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th Edition (AT8) and (2) reviewing the draft manuscripts and recommendations to assess the usability of the guidelines and the feasibility of implementation of AT9 recommendations.

To address issues of economic efficiency six health economist-physicians were included on the AT9 topic panels charged with making recommendations. These resource consultants were selected and approved through identical procedures to those for topic editors and panel members.

Ensuring Consistency Across Articles

A number of strategies were used to ensure consistency across articles, and one panel member participated extensively in the formulation of clinical questions for each article. To ensure consistency of judgments regarding bleeding, another panel member was responsible for standardizing the approach to bleeding outcomes and participated in multiple topic panels. Additionally, to ensure consistency in the trade-offs between thrombotic and bleeding events, all articles used the same ratings of values and preferences (described in more detail in the methodology companion [see the "Availability of Companion Documents" field]). Because some of the same evidence summaries were relevant to several articles, five individuals were chosen to participate in each of the articles addressing coronary artery disease, stroke, and peripheral arterial disease.

In AT9, prevention of venous thromboembolism (VTE) is addressed in three articles as opposed to a single article as was done in AT8. The prevention topic editors and deputy editors and those of the stroke article (which includes thromboprophylaxis recommendations) participated in multiple conference calls to develop and harmonize the approach to prevention and to ensure consistency among final recommendations. Topic editors consulted with one another when issues overlapped. For example, the decision regarding the use of a vitamin K antagonist, aspirin, and clopidogrel simultaneously in patients with atrial fibrillation, valvular disease, and intravascular stents is relevant for the atrial fibrillation, coronary, and peripheral arterial disease articles. Topic panels deferred to the Evidence-Based Management of Anticoagulant Therapy AT9 topic panel for recommendations related to the dosing and monitoring of anticoagulation therapies.

The AT9 Executive Committee met at least once a month and regularly issued statements of clarification of methods to topic editors and deputy editors (e.g., use of fixed- or random-effects models for meta-analysis), conflict of interest, preparation of tables, and issues of style and presentation. All these statements were communicated directly to the topic editors and deputy editors and made available in a central repository accessible to all AT9 panelists. The chair of the Executive Committee was available for resolving any challenging issues related to the aforementioned topics. Between September 2009 and September 2010, two members of the Executive Committee held regular (every 3 months), separate conference calls with each topic editor and deputy editor during which they addressed questions and concerns. Finally, the chair of the Executive Committee reviewed every article to ensure consistency of evidence presentation, evaluation, and writing style. Refer to the methodology companion for further information on the approach used to ensure consistent language in writing.

Formulating Recommendations

Following approaches recommended by the GRADE Working Group, the topic editor, in some cases aided by a panelist without conflicts, formulated the draft recommendations. The formulation of recommendations considered the balance between the desirable and undesirable consequences of an intervention; the quality of evidence; the variability in patient values and preferences; and, on occasion, resource use issues. The recommendations were graded as strong when desirable effects were much greater than undesirable effects or vice versa. Strong recommendations were worded as "The expert panel recommends" and labeled 1. Recommendations were graded as weak when desirable effects were not clearly greater or less great than undesirable effects. Weak recommendations were worded as "The expert panel suggests" and labeled 2. The rating of the quality of the evidence—high, A; moderate, B; or low, C—is provided with the strength of each recommendation.

Finalizing Recommendations

The topic panel members without primary conflicts discussed draft recommendations. Initial discussions generally led to a consensus at the article level on the quality of evidence and the direction and strength of recommendations. At least two members of the Executive Committee reviewed in detail drafts of articles, including recommendations. Written critiques were prepared and returned to the authors for revision. Articles were then made available to the entire AT9 panel.

Recommendations on which topic panels had difficulty coming to a consensus were discussed at a final conference in February 2011 attended by the topic editors and deputy editors and at least one other panel member from each article. Prior to the conference, all AT9 panelists updated their conflict of interest disclosures. The ACCP invited a number of clinical organizations with interest in the guideline topic to attend the final conference as observers.

At this final conference, a representative of each article presented potentially controversial issues in their article's recommendations. Following discussion, which included those present and those attending by video conference, all panelists without primary conflicts of interest voted on each
recommendation. The voting process used a GRADE grid and required that for a strong recommendation, ≥80% of those voting had to agree that a strong recommendation was appropriate.

The AT9 Executive Committee members harmonized the articles and resolved remaining disagreements among them through facilitated discussion with topic editors and deputy editors without primary conflicts. All major correspondence and decisions at the final conference were recorded in written and audio formats and are available on request to science@chestnet.org.

See the methodology companion (see the "Availability of Companion Documents" field) for information on accounting for patient values and preferences in recommendations.

Rating Scheme for the Strength of the Recommendations

<table>
<thead>
<tr>
<th>Grade of Recommendation*</th>
<th>Benefit vs. Risk and Burdens</th>
<th>Methodologic Quality of Supporting Evidence</th>
<th>Implications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong recommendation, high-quality evidence, Grade 1A</td>
<td>Benefits clearly outweigh risk and burdens or vice versa</td>
<td>Consistent evidence from randomized controlled trials (RCTs) without important limitations or exceptionally strong evidence from observational studies</td>
<td>Recommendation can apply to most patients in most circumstances. Further research is very unlikely to change confidence in the estimate of effect</td>
</tr>
<tr>
<td>Strong recommendation, moderate-quality evidence, Grade 1B</td>
<td>Benefits clearly outweigh risk and burdens or vice versa</td>
<td>Evidence from RCTs with important limitations (inconsistent results, methodologic flaws, indirect or imprecise), or very strong evidence from observational studies</td>
<td>Recommendation can apply to most patients in most circumstances. Higher quality research may well have an important impact on confidence in the estimate of effect and may change the estimate</td>
</tr>
<tr>
<td>Strong recommendation, low- or very-low-quality evidence, Grade 1C</td>
<td>Benefits clearly outweigh risk and burdens or vice versa</td>
<td>Evidence for at least one critical outcome from observational studies, case series, or from RCTs with serious flaws or indirect evidence</td>
<td>Recommendation can apply to most patients in many circumstances. Higher-quality research is likely to have an important impact on confidence in the estimate of effect and may well change the estimate</td>
</tr>
<tr>
<td>Weak recommendation, high-quality evidence, Grade 2A</td>
<td>Benefits closely balanced with risks and burden</td>
<td>Consistent evidence from RCTs without important limitations or exceptionally strong evidence from observational studies</td>
<td>The best action may differ depending on circumstances or patient or society values. Further research is very unlikely to change confidence in the estimate of effect</td>
</tr>
<tr>
<td>Weak recommendation, moderate-quality evidence, Grade 2B</td>
<td>Benefits closely balanced with risks and burden</td>
<td>Evidence from RCTs with important limitations (inconsistent results, methodologic flaws, indirect or imprecise) or very strong evidence from observational studies</td>
<td>Best action may differ depending on circumstances or patient or society values. Higher-quality research may well have an important impact on confidence in the estimate of effect and may change the estimate</td>
</tr>
<tr>
<td>Weak recommendation, low- or very-low-quality evidence, Grade 2C</td>
<td>Uncertainty in the estimates of benefits, risks, and burden; benefits, risk, and burden may be closely balanced</td>
<td>Evidence for at least one critical outcome from observational studies, case series, or RCTs, with serious flaws or indirect evidence</td>
<td>Other alternatives may be equally reasonable. Higher-quality research is likely to have an important impact on confidence in the estimate of effect and may well change the estimate</td>
</tr>
</tbody>
</table>

*The guideline developers use the wording recommend for strong (Grade 1) recommendations and suggest for weak (Grade 2) recommendations.

Cost Analysis

General

Resource Use Issues

In addressing resource use (cost) issues in Antithrombotic Therapy and Prevention of Thrombosis, 9th ed (AT9), the expert panel followed
previously developed principles. In particular, the panel restricted economic evaluation to recommendations in which it was plausible that resource use considerations might change the direction or strength of the recommendation and in which high-quality economic evaluations were available. When this was not the case, the panel did not consider resource use in the recommendations.

Six clinicians with the requisite expertise in decision and economic analyses participated in the guideline development process; each article had the benefit of one of these experts as a full committee member. The following subsections present key points in the process of considering resource allocation issues in the recommendations.

Overview of the Process

Panelists, in consultation with resource use consultants, determined questions for which resource use might change the direction or strength of recommendations. For those questions, the panel sought high-quality economic analyses. If such analyses were available, the panel applied the evidence regarding resource use to the relevant recommendation. If net costs or marginal cost-effectiveness ratios were very high, panelists considered rating down the quality of evidence for an intervention from high to low or possibly changing the direction of the recommendation using guides described in the section "Criteria for Resource Allocation Issues to Affect Recommendations—Thresholds for Cost-Effectiveness" in the methodology companion (see the "Availability of Companion Documents" field).

Identifying the Literature

The Oregon Health & Science University Evidence-based Practice Center conducted thorough literature searches for economic analyses relevant to the different AT9 articles. The resource use experts supplemented these by searches focused on the specific questions of interest for each article. The searches were conducted in Medline and the Cochrane Central Register of Clinical Trials. On the basis that data from studies appreciably more than a decade old would not reflect the current situation, searches were restricted to published studies from 1999 forward. Thus, bibliographic database searches encompassed publications from January 1999 forward: The end date varied across articles and ranged between November 2009 and March 2010 when the searches were executed.

Evaluating the Evidence

A standardized data extraction form was used to ensure uniform evaluation of the quality of relevant economic analyses. Quality assessment was based on published criteria and included specification of perspective of analysis (e.g., societal, health system), appropriateness of time horizon (preferably lifetime), use of high-quality evidence for probabilities and rates, use of high-quality sources for costs (e.g., primary data, Medicare payments, claims data as proxies), use of appropriate methods for measurement of preferences, and performance of sensitivity analyses to explore uncertainty (both deterministic and probabilistic).

Criteria for Resource Allocation Issues to Affect Recommendations—Thresholds for Cost-Effectiveness

The results of economic analyses may either increase the strength of an otherwise weak recommendation or weaken the strength of a strong recommendation. If cost-effectiveness studies bolstered an already strong recommendation, no change to the recommendation was necessary. The panel chose the following thresholds for cost-effectiveness considerations affecting recommendations:

1. When the clinical evidence warrants a strong recommendation for A over B:
   a. Strong recommendation favoring A when high-quality evidence from economic evaluations shows that A costs <3 times the gross domestic product (GDP) per capita (approximately US $150,000) per quality-adjusted life year (QALY) gained relative to B
   b. Weak recommendation favoring A when high-quality evidence from economic evaluations shows that A costs 3 to 5 times the GDP per capita (~$150,000-$250,000) per QALY gained relative to B
   c. Weak recommendation favoring B when high-quality evidence from economic evaluations shows that A costs >5 times the GDP per capita (~$250,000) per QALY gained relative to B

2. When the clinical evidence warrants a weak recommendation for A over B:
   a. Strong recommendation favoring A if A results in cost savings of >10% to 20% of the GDP per capita (~$5,000-$10,000) relative to B (Cost savings must represent all downstream costs and not just the actual cost of the intervention, and analysis must demonstrate a high level of confidence that there is a cost savings.)
   b. Continued weak recommendation favoring A when B is marginally more costly than A (<10% the GDP per capita)
   c. Continued weak recommendation favoring A when A costs 0 to 5 times the GDP per capita per QALY gained relative to B
   d. Weak recommendation favoring B if A costs >5 times the GDP per capita (~$250,000) per QALY gained relative to B

Extension of Economic Analyses to Low- and Middle-Income Countries

Although certain interventions may be cost-effective in high-income countries (e.g., <$20,000 per QALY gained), in poor countries, $20,000 gained per QALY may be prohibitive. The choice of a threshold will vary depending on who is making resource allocation decisions. To facilitate
the use of already published cost-effectiveness analyses, the World Health Organization (WHO), through its WHO-CHOICE (Choosing Interventions that are Cost Effective) program has used criteria suggested by the Commission on Macroeconomics and Health. Interventions that cost <1 times the average per-capita income for a given country or region per QALY gained are considered very cost-effective. Interventions that cost up to three times the average per-capita income per QALY gained are still considered cost-effective, whereas those that exceed this level are not considered to be cost-effective. To facilitate this process, WHO has developed tables of such threshold values for different regions and countries around the world. Thus, the thresholds discussed in the previous section have been defined in terms of GDP per capita. Although referencing thresholds for cost-effectiveness to average per-capita income in middle- and low-income countries can help to extend results of economic analyses performed in high-income countries, such analyses may be less relevant in low-income countries because of significantly different material and labor costs and, thus, may be difficult to extrapolate. Furthermore, the comparator strategies may not be feasible or customary in these locales.

Specific to This Guideline

Thromboprophylaxis Following Cesarean Section

There are no relevant cost-effectiveness data in this setting using unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH); however, in one study modeling the cost-effectiveness of intermittent pneumatic compression, this intervention was considered cost-effective when the incidence of postcesarean section deep vein thrombosis (DVT) was at least 6.8 of 1,000 (see Tables S13 and S14 in the data supplement to the original guideline).

Method of Guideline Validation

External Peer Review

Internal Peer Review

Description of Method of Guideline Validation

The American College of Chest Physicians (ACCP) Health and Science Policy (HSP) Committee established a process for the thorough review of all ACCP evidence-based clinical practice guidelines. After final review by the Antithrombotic Therapy and Prevention of Thrombosis, 9th ed (AT9) Executive Committee, the guidelines underwent review by the Cardiovascular and Pulmonary Vascular NetWorks of the ACCP, the HSP Committee, and the ACCP Board of Regents. The latter two groups had the right of approval or disapproval but usually worked with the topic panelists and editors to make necessary revisions prior to final approval. Both the HSP Committee and the Board of Regents identified primary reviewers who read the full set of articles, and the remaining HSP Committee members were responsible for reviewing several articles each. The reviewers considered both content and methodology as well as whether there was balanced reporting and adherence to HSP Committee processes. All reviewers were vetted through the same conflict of interest disclosure and management process described in the "Description of Methods Used to Formulate Recommendations" field. Finally, the Editor in Chief of CHEST read and forwarded the manuscripts for independent, external peer review prior to acceptance for publication. No recommendations or assessments of the quality of the evidence could be changed without the express approval of the topic panel members, AT9 Executive Committee, HSP Committee, and ACCP Board of Regents.

This guideline is endorsed by the American Association for Clinical Chemistry, the American College of Clinical Pharmacy, the American Society of Health-System Pharmacists, the American Society of Hematology, and the International Society on Thrombosis and Haemostasis.

Evidence Supporting the Recommendations

Type of Evidence Supporting the Recommendations

The type of supporting evidence is identified and graded for each recommendation (see the "Major Recommendations" field).

Benefits/Harms of Implementing the Guideline Recommendations

Potential Benefits
Potential Benefits

Appropriate monitoring and management of pregnant and lactating patients with venous thromboembolism, thrombophilia, or receiving antithrombotic therapy.

Potential Harms

- Maternal complications of anticoagulant therapy are similar to those seen in nonpregnant patients and include bleeding (for all anticoagulants) as well as heparin-induced thrombocytopenia (HIT), heparin-associated osteoporosis, bruising, local allergic reactions, and pain at injection sites for heparin-related compounds.
- Adverse skin reactions to unfractionated heparin (UFH) include bruising, urticarial rashes, erythematosus well-circumscribed lesions (because of a delayed type 4 hypersensitivity action), skin necrosis (often due to vasculitis), and HIT. The true incidence of skin reactions caused by UFH is unknown.
- Adverse skin reactions similar to those seen with UFH can also occur with low molecular weight heparin (LMWH), although the frequency appears reduced. The reported incidence ranges from 1.8% to 29%. Most LMWH-induced skin lesions are benign; however, HIT should be excluded.
- Vitamin K antagonists cross the placenta and have the potential to cause fetal wastage, bleeding in the fetus, and teratogenicity.
- UFH does not cross the placenta and, therefore, does not have the potential to cause fetal bleeding or teratogenicity; although bleeding at the uteroplacental junction is possible.
- Aspirin crosses the placenta, and animal studies have shown that aspirin may increase the risk of congenital anomalies. One population-based study did note an increased risk of miscarriage with aspirin use that was greatest when aspirin was taken around the time of conception; however, the number of aspirin users was small, aspirin doses were unknown, and users may have had conditions associated with an increased risk of pregnancy loss. A meta-analysis of seven randomized trials in which women started aspirin later in pregnancy failed to establish or refute an increase in risk of miscarriage with aspirin compared with placebo.
- Although aspirin is a polar, acidic drug that is poorly lipid soluble and highly bound to plasma proteins, maternal aspirin ingestion is associated with excretion of salicylates into breast milk. There are, therefore, potential risks of platelet dysfunction and gastrointestinal (GI) bleeding in nursing infants of mothers using high doses of this drug. Metabolic acidosis has been reported in breast-fed infants of mothers taking several grams of aspirin per day. Theoretically, nursing infants of mothers taking aspirin could be at risk for developing Reye syndrome.
- Although elastic stockings have been associated with skin breakdown when used poststroke, this complication is much less likely to occur in young women. Elastic stockings and intermittent pneumatic compression may be inconvenient and cumbersome to use.

Refer to the original guideline document for additional information on maternal, fetal, and infant complications of anticoagulant therapy during pregnancy and breastfeeding.

Qualifying Statements

The evidence-based practice guidelines published by The American College of Chest Physicians ("ACCP") incorporate data obtained from a comprehensive and systematic literature review of the most recent studies available at the time. Guidelines are intended for general information only, are not medical advice, and do not replace professional medical care and physician advice, which always should be sought for any specific condition. Furthermore, guidelines may not be complete or accurate because new studies that have been published too late in the process of guideline development or after publication are not incorporated into any particular guideline before it is disseminated. The ACCP and its officers, regents, governors, executive committee, members and employees (the "ACCP Parties") disclaim all liability for the accuracy or completeness of a guideline, and disclaim all warranties, express or implied. Guideline users always are urged to seek out newer information that might impact the diagnostic and treatment recommendations contained within a guideline. The ACCP Parties further disclaim all liability for any damages whatsoever (including, without limitation, direct, indirect, incidental, punitive, or consequential damages) arising out of the use, inability to use, or the results of use of a guideline, any references used in a guideline, or the materials, information, or procedures contained in a guideline, based on any legal theory whatsoever and whether or not there was advice of the possibility of such damages.

Through a comprehensive and systematic literature review, the ACCP's evidence-based clinical practice guidelines incorporate data from the existing peer-reviewed literature. This literature meets the prespecified inclusion criteria for the clinical research question, which ACCP
considers, at the time of publication, to be the best evidence available for general clinical information purposes. This evidence is of varying quality from original studies of varying methodological rigor. The ACCP recommends that performance measures for quality improvement, performance-based reimbursement, and public reporting purposes should be based on rigorously developed guideline recommendations. However, not all recommendations graded highly according to the ACCP grading system (1A, 1B) are necessarily appropriate for development into such performance measures, and each one should be analyzed individually for importance, feasibility, usability, and scientific acceptability (National Quality Forum criteria). Performance measures developers should exercise caution in basing measures on recommendations that are graded 1C, 2A, 2B, and 2C, according to the ACCP Grading System as these should generally not be used in performance measures for quality improvement, performance-based reimbursement, and public reporting purposes.

- **Limitations of Methods:** Although encouraged to use Evidence Profiles and Summary of Findings tables for all recommendations, there were some for which the authors were unable to produce such tables. However, those recommendations used an evidence-based systematic review and assessment of relevant studies. Some recommendations would have benefited from meta-analyses that would have clarified aspects of the evidence. Although panelists were instructed in completing the value and preference rating exercise to estimate patient values and preferences rather than to use their own, it cannot be assured that they succeeded in all instances.

**Implementation of the Guideline**

**Description of Implementation Strategy**

An implementation strategy was not provided.

**Implementation Tools**

Quick Reference Guides/Physician Guides

For information about availability, see the *Availability of Companion Documents* and *Patient Resources* fields below.

**Institute of Medicine (IOM) National Healthcare Quality Report Categories**

**IOM Care Need**

- Getting Better
- Living with Illness
- Staying Healthy

**IOM Domain**

- Effectiveness
- Patient-centeredness
- Safety

**Identifying Information and Availability**

Bibliographic Source(s)
Adaptation

Not applicable: The guideline was not adapted from another source.

Date Released

2001 Jan (revised 2012 Feb)

Guideline Developer(s)

American College of Chest Physicians - Medical Specialty Society

Source(s) of Funding

The Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines received support from the National Heart, Lung, and Blood Institute [R13 HL104758] and Bayer Schering Pharma AG. Support in the form of educational grants were also provided by Bristol-Myers Squibb; Pfizer, Inc; Canyon Pharmaceuticals; and sanofi-aventis US.

The sponsors played no role in the development of these guidelines. Sponsoring organizations cannot recommend panelists or topics, nor are they allowed prepublication access to the manuscripts and recommendations.

Guideline Committee

American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel

Composition of Group That Authored the Guideline

Primary Authors: Shannon M. Bates, MDCM; Ian A. Greer, MD, FCCP; Saskia Middeldorp, MD, PhD; David L. Veenstra, PharmD, PhD; Anne-Marie Prabulos, MD; and Per Olav Vandvik, MD, PhD

Executive Committee: Gordon H. Guyatt, MD, FCCP (Chair); Elie A. Akl, MD, MPH, PhD; Mark Crowther, MD; David D. Gutterman, MD, FCCP; Holger J. Schünemann, MD, PhD, FCCP; Sandra Zelman Lewis, PhD, ACCP; Joe Ornelas, DC

Panelists: Walter Ageno, MD; Pablo Alonso-Coello, MD, PhD; Sonia S. Anand, MD, PhD; Juan I. Arcelus, MD, PhD; Trevor P. Baglin, MBChB, PhD; Alex A. Balekian, MD, MSHS; Shannon M. Bates, MDCM; Sergio Bellmunt, MD, Neera Bhatnagar, MLIS; Robert Bona, MD; Henri Bounamaux, MD; Anthony K. C. Chan, MBBS; Clifford W. Colwell Jr, MD; Anthony J. Comerota, MD; Deborah J. Cook, MD, MSc(Epi); Michael H. Criqui, MD, MPH; Catherine Curley, MD; Mary Cushman, MD; Ola E. Dahl, MD; Antonio L. Dans, MD, Bruce L. Davidson, MD, MPH, FCCP; Francesco Dentali, MD; James D. Douketis, MD, FCCP; Andrew S. Dunn, MD; Sharil Ebrahim, MS; Mark H. Eckman, MD; John W. Eikelboom, MBBS; Yngve Falck-Ytter, MD; Margaret C. Fang, MD, MPH; Jason Fish, MD, MS; Charles W. Francis, MD; Stephen E. Frenses, MD, FCCP; Alexander S. Gallus, MBBS; David A. García, MD; Alan S. Go, MD; Neil A. Goldenberg, MD, PhD; Samuel Z. Goldhaber, MD, FCCP; Steven Goodacre, MBChB, PhD; Joel M. Gore, MD; Michael K. Gould, MD, FCCP; Ian A. Greer, MD, FCCP; Randolph Guzman, MD, RVT; Jonathan L. Halperin, MD; John A. Heit, MD; Jack Hirsh, MD, FCCP; Anne Holbrook, MD, PharmD; Patricia A. Howard, PharmD; Michael Hughes, PhD; Elaine M. Hylek, MD, MPH; Rebecca N. Ichord, MD; Roman Jaeschke, MD; Amir K. Jaffer, MD; Milosz Jankowski, MD, PhD; Norman A. Johanson, MD; Janna M. Journeycake, MD, MSCS; Susan R. Kahn, MD; Paul J. Karanicolas, MD, PhD; Clive Kearon, MD, PhD; Pooja Khatri, MD; Russell C. Klein, MD; Michael J. Kovacs, MD; Regina Kunz, MD, MSc(Epi); Deirdre A. Lane, PhD; Eddy S. Lang, MDCM; Maarten G. Lansberg, MD, PhD; Hoang Le, MD, FCCP; Wendy Lim, MD, A. Michael Lincoff, MD; Lori-Ann Linkins, MD; Gregory Y. H. Lip, MD; Samantha MacLean, MSc; Regina Makdissi, MD; Warren J. Manning,
Financial Disclosures/Conflicts of Interest

All panelists were required to disclose both financial conflicts of interest, such as receipt of funds for consulting with industry, and intellectual conflicts of interest, such as publication of original data bearing directly on a recommendation. Financial and intellectual conflicts of interest were classified as primary (more serious) or secondary (less serious). The operational definition of primary intellectual conflicts of interest included authorship of original studies and peer-reviewed grant funding (government, not-for-profit organizations) directly bearing on a recommendation. The operational definition of primary financial conflicts of interest included consultancies, advisory board membership, and the like from industry. Topic editors had no primary conflicts of interest, as noted. Some deputy editors, who were clinical experts in the topic of the article, had relevant primary conflicts of interest. The American College of Chest Physicians (ACCP) Health and Science Policy (HSP) Committee deemed some of these conflicts serious enough to require “management.” Management involved more frequent updates of disclosures than required of the approved panelists without any conflicts and recusal from activities relevant to that conflict.

Topic panel members, including the deputy editor, with primary conflicts related to a particular recommendation did not participate in the final deliberations that led to the decision regarding the direction or strength of a recommendation, nor did they vote on recommendations for which they were primarily conflicted. Panelists with primary conflicts could, however, participate in discussions and offer their opinions on interpretations of the evidence. Readers will find a record of panelist conflicts of interest on a recommendation-by-recommendation basis in the online data supplement.

In summary, the authors have reported to CHEST the following conflicts of interest: Dr Bates has received honoraria for lectures from Leo Pharma, Inc. (anticoagulant manufacturer), Sanofi-Aventis Canada (anticoagulant manufacturer), Boehringer Ingelheim GmbH (anticoagulant manufacturer), and Thrombosis Education, Ltd. Dr Greer has received honoraria for lectures and advisory board contributions from Leo Pharma and Sanofi-Aventis. Dr Middeldorp has received unrestricted research funding from GlaxoSmithKline plc and MedaPharma for the ALIFE study and has received speakers fees from GlaxoSmithKline plc; Boehringer Ingelheim GmbH; Bayer Healthcare Pharmaceuticals; Leo Pharma, Inc. Dr Vandvik is a member of and prominent contributor to the GRADE Working Group. Drs Veenstra and Prabulos have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Guideline panel members, including the chair, and members of the Health & Science Policy Committee are blinded to the funding sources. Further details on the Conflict of Interest Policy are available online at http://chestnet.org.

Guideline Availability

Available to subscribers of Chest - The Cardiopulmonary and Critical Care Journal.

Print copies: Available from the American College of Chest Physicians, Products and Registration Division, 3300 Dundee Road, Northbrook IL 60062-2348.

Availability of Companion Documents

The following are available:


Available to subscribers of Chest - The Cardiopulmonary and Critical Care Journal.

Print copies: Available from the American College of Chest Physicians, Products and Registration Division, 3300 Dundee Road, Northbrook IL 60062-2348.

Patient Resources

None available

NGC Status

This summary was completed by ECRI on July 12, 2001. The information was verified by the guideline developer on October 2001. This NGC summary was updated by ECRI on December 9, 2004. The updated information was verified by the guideline developer on January 12, 2005. This summary was updated by ECRI on March 6, 2007 following the U.S. Food and Drug Administration (FDA) advisory on Coumadin (warfarin sodium). This summary was updated by ECRI Institute on June 22, 2007 following the U.S. Food and Drug Administration (FDA) advisory on heparin sodium injection. This summary was updated by ECRI Institute on September 7, 2007 following the revised U.S. Food and Drug Administration (FDA) advisory on Coumadin (warfarin). This summary was updated by ECRI Institute on March 14, 2008 following the updated FDA advisory on heparin sodium injection. This NGC summary was updated by ECRI Institute on December 9, 2008. The updated information was verified by the guideline developer on January 7, 2009. This summary was updated by ECRI Institute on July 27, 2010 following the FDA drug safety communication on Heparin. This NGC summary was updated by ECRI Institute on May 2, 2012. This summary was updated by ECRI Institute on March 10, 2014 following the U.S. Food and Drug Administration advisory on Low Molecular Weight Heparins.
Copyright Statement

This NGC summary is based on the original guideline, which is subject to the guideline developer’s copyright restrictions.

Disclaimer

NGC Disclaimer

The National Guideline Clearinghouseâ€¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.